The company announced the completion of enrollment in its PEAK trial, a pivotal study for patients with imatinib-resistant gastrointestinal stromal tumors, and the initiation of a Phase 1 trial for a ...

He worked with chemists at Novartis to develop a drug that would bind to the mutant protein like a key in a lock. Novartis ...

Business Highlights & Milestones Completed enrollment in PEAK, a randomized, open-label, global Phase 3 trial evaluating bezuclastinib in combination with sunitinib vs sunitinib alone in patients with ...

Scientists from Duke-NUS Medical School and their collaborators have identified an inherited genetic variation prevalent ...

Scientists investigated how an inherited genetic variation common among East Asians contributes to drug resistance in cancer cells, driving more aggressive cancer growth. The team trialled a precision ...

Topline results from registration-directed trial of ziftomenib in R/R NPM1-mutant AML expected in early 2025; Phase 1 results published in The Lancet Oncology – – Data from 100 patients in Phase 1a do ...

Targeted therapy revolutionized cancer treatment, with gene fusions leading the way when the FDA approved imatinib in 2001 to ...

Duke-NUS scientists investigated how an inherited genetic variation common among East Asians contributes to drug resistance ...

For chronic myeloid leukemia (CML) patients, there is a promising new first-line drug approval with asciminib (brand name ...

More than 95% of chronic myeloid leukemia (CML) and 20%-30% of acute lymphoblastic leukemia (ALL) patients express the fusion ...

A new approach helps examine the proportion of cancerous and healthy stem cells in patients with chronic myeloid leukemia and how this influences treatment outcomes.